Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up tp this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 344 treatment comparisons .

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
NCT04344730 ; EudraCT 2020-001457-43
COVIDICUS
Bouadma L, JAMA Intern Med, 2022
Full text
Commentary
Commentary
Mixed

Dexamethasone Low Dose

Dexamethasone Low Dose

RCT Patients with confirmed COVID-19 (severe-critical) admitted to 19 centers in France. N=550
Some concerns
Details

Full description

New
NCT04332835
Rojas M, BMC Infect Dis, 2022
Full text
Commentary
Mixed

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to three centers in Colombia N=101
Some concerns
Details

Full description

New
NCT04362176
PassITON
Self WH, Chest, 2022
Full text
Commentary
Public/non profit

Convalescent plasma

Placebo

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 25 centers in USA. N=974
Low
Details

Full description

New
NCT04402203
Rahman SMA, Clin Infect Pract, 2022
Full text
Commentary
Private

Favipiravir

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 4 centers in Bangladesh. N=57
High
Details

Full description

New
IRCT20210223050466N1
Dastenae ZH, Int J Infect Dis, 2022
Full text
Commentary
Commentary
Public/non profit

Methylprednisolone

Dexamethasone

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Iran. N=143
Some concerns
Details

Full description

NCT04794803; EudraCT 2020-001645-40
Landoni G, Infect Dis Ther, 2022
Full text
Commentary
Commentary
Private

Reparixin

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Italy (3 centers) and Brazil (1 center). N=56
High
Details

Full description

jRCT2031210350
Mukae H, medRxiv, 2022 b
Full text
Commentary
Commentary
Mixed

Ensitrelvir 125

Ensitrelvir 250

Placebo

RCT Patients with confirmed COVID-19 (mild ambulatory) treated or isolated at 87 centers in Japan and South Korea. N=428
Some concerns
Details

Full description

NCT05205759
MANTICO
Mazzaferri F, medRxiv, 2022
Full text
Commentary
Commentary
Public/non profit

LY-CoV555+LY-CoV016

LY-CoV555+LY-CoV016

Sotrovimab

Casirivimab+Imdevimab (REGN-COV2)

Sotrovimab

Casirivimab+Imdevimab (REGN-COV2)

RCT Outpatients with confirmed COVID-19 (mild) treated at 20 centers in Italy. N=319
Some concerns
Details

Full description

NCT04803370
Bargay-Lleonart J, J Clin Med, 2022
Full text
Commentary
Commentary
Public/non profit

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 3 hospitals in Spain. N=55
Some concerns
Details

Full description

jRCT2031210350
Mukae H, medRxiv, 2022 a
Full text
Commentary
Commentary
Mixed

Ensitrelvir 125

Ensitrelvir 250

Placebo

RCT Outpatients and inpatients with confirmed COVID-19 (asymptomatic to mild) treated or isolated at 56 centers in Japan. N=69
Some concerns
Details

Full description